Effects of NBI-1065845 on Drug Interactions in Healthy Adults
Study Overview
This study looked at the impact of NBI-1065845, a potential treatment for major depressive disorder, on the metabolism of midazolam and ethinyl estradiol-levonorgestrel in healthy adults. The results provide important insights into potential drug interactions.
Key Findings
After multiple doses of NBI-1065845, it was found that NBI-1065845 does not induce the CYP3A enzyme. This suggests that NBI-1065845 can be safely used with drugs metabolized by CYP3A.
Value for Clinical Practice
These findings support the safe coadministration of NBI-1065845 with CYP3A substrates, providing practical guidance for clinicians when prescribing medications.
Integrating Clinical Trials into Medical Practice
Clinical trials play a crucial role in developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research, making it easier for clinicians to access important medical knowledge.
Streamlining Healthcare Operations
Efficient operations are essential in today’s healthcare environment. Our mobile apps support scheduling, treatment monitoring, and telemedicine, enabling clinics to manage patient care and expand services digitally.
Enhancing Workflows with AI
By leveraging AI, clinics can improve workflows, enhance patient outcomes, and reduce paper-based routines. Learn more about how our solutions can benefit your practice at aidevmd.com.
